...Chrystal A. Landry; Julia Blanter; Meng Ru; Julie Fasano; Paula Klein; Theresa Shao; Aarti Bhardwaj; Amy Tiersten Introduction: The release of tumor-associated antigens with cytotoxic chemotherapy treatment may enhance the response to immune checkpoint blockade. Eribulin is a microtubule inhibitor...

...Oskar Steinbrecher; Thomas Brodowicz; Markus Raderer; Anke Scharrer; Johannes Fabsits; Wolfgang Lamm Introduction: Soft tissue sarcomas are rare and heterogenous malignancies with a poor prognosis in advanced disease stages. Eribulin is used in metastatic liposarcoma (LPS) patients, who have failed...

... who received eribulin for metastatic breast cancer (MBC) collected from 14 hospitals across the UK. Methods: Anonymized data were collected retrospectively from patients with MBC who had received eribulin. The data included the hormone-receptor status, histological diagnosis, age, prior chemotherapy...

... of a 40-year-old woman with MBC and associated lung, bone, liver, and brain metastases, who experienced a time to progression of several months with eribulin after whole-brain radiotherapy (WBRT), 2 lines of chemotherapy, and 1 line of hormonal therapy, maintaining a good toxicity profile. Discussion...

...Guido Giordano; Antonio Febbraro; Erica Quaquarini; Anna Turletti; Rebecca Pedersini; Mimma Raffaele; Federica Villa; Rosalba Rossello; The Italian Eribulin Working Group Liver metastases are very common in metastatic breast cancer (MBC); current treatments for these lesions are based on systemic...

...Raffaele Nettuno; Carmine Menditto Eribulin, a non-taxane inhibitor of microtubule dynamics, is approved for the treatment of metastatic breast cancer patients after progression with anthracyclines and taxanes. Nevertheless, to our knowledge, information on its use in dialytic patients...

...Rebecca Pedersini; Lucia Vassalli; Melanie Claps; Antonella Tulla; Filippo Rodella; Salvatore Grisanti; Vito Amoroso; Elisa Roca; Edda Lucia Simoncini; Alfredo Berruti Objectives: The aim of this study was to investigate efficacy and safety of eribulin in heavily pretreated patients with advanced...

... with eribulin. The patient initially experienced progressive disease after a standard anthracycline/taxane-based adjuvant chemotherapy, a first-line treatment for metastatic disease with paclitaxel-bevacizumab, and a second-line maintenance treatment with bevacizumab and capecitabine. Eribulin was administered...

...Rita De Sanctis; Elisa Agostinetto; Giovanna Masci; Emanuela Ferraro; Agnese Losurdo; Alessandro Viganò; Lidija Antunovic; Monica Zuradelli; Rosalba Maria Concetta Torrisi; Armando Santoro Objectives: Predictive factors of response to eribulin are lacking. We aimed to investigate the activity...